Bayer AG (FRA:BAYN) has been given a €125.00 ($147.06) target price by J P Morgan Chase & Co in a research report issued on Wednesday, November 1st. The brokerage currently has a “buy” rating on the healthcare company’s stock. J P Morgan Chase & Co’s price objective would suggest a potential upside of 15.05% from the company’s previous close.
A number of other equities analysts also recently issued reports on BAYN. Goldman Sachs Group, Inc. (The) set a €125.00 ($147.06) price target on Bayer AG and gave the stock a “buy” rating in a research report on Monday, July 24th. Deutsche Bank AG set a €124.00 ($145.88) target price on Bayer AG and gave the company a “buy” rating in a report on Monday, July 10th. Citigroup Inc. reaffirmed a “buy” rating on shares of Bayer AG in a report on Wednesday, July 5th. Commerzbank Ag set a €124.00 ($145.88) price target on Bayer AG and gave the company a “buy” rating in a report on Monday, August 28th. Finally, Sanford C. Bernstein set a €126.00 ($148.24) price target on Bayer AG and gave the company a “buy” rating in a report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of €122.43 ($144.03).
Shares of Bayer AG (BAYN) traded up €1.10 ($1.29) during mid-day trading on Wednesday, hitting €108.65 ($127.82). The stock had a trading volume of 2,620,224 shares. Bayer AG has a fifty-two week low of €86.06 ($101.25) and a fifty-two week high of €123.82 ($145.67).
Bayer AG Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with our FREE daily email newsletter.